Altimmune (ALT) Fundamental Analysis: Revenue, Earnings & Valuation

5.31 / 10

Netural

Fundamental metrics score 5.3/10. Revenue‑MV and Cash‑MV are strong, inventory turnover is solid, but Fixed‑Asset turnover and Asset‑MV lag. PB‑ROE is favorable. Overall, the company displays balanced fundamentals with modest upside.

Analysis Checks(8/10)

Revenue-MV

Value-7.53

Score2/3

Weight21.31%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value105.00

Score2/3

Weight-2.10%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.37%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.96%

1M Return1.69%

PB-ROE

Value-0.07

Score3/3

Weight27.25%

1M Return9.74%

Income tax / Total profit (%)

Value0.77

Score2/3

Weight2.32%

1M Return1.04%

Fixed assets turnover ratio

Value0.11

Score1/3

Weight-2.42%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.05%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight6.82%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight15.43%

1M Return5.94%

Is ALT undervalued or overvalued?

ALT scores 5.31/10 on fundamentals and holds a Fair valuation at present. Backed by its -50.57% ROE, -214860.98% net margin, -4.46 P/E ratio, 1.75 P/B ratio, and 25.37% earnings growth, these metrics solidify its Netural investment rating.